ROCKVILLE, Md., Jan. 6 /PRNewswire/ -- FDA has approved two drugs to treat
two different behavioral problems affecting some dogs -- Clomicalm Tablets
(clomipramine hydrochloride) to be used as part of a comprehensive behavioral
management program to treat separation anxiety in dogs greater than six months
of age, and Anipryl Tablets (selegiline hydrochloride, L-deprenyl
hydrochloride) to control the clinical signs associated with canine Cognitive
Dysfunction Syndrome (CDS).
Separation anxiety is a complex behavior disorder displayed when the
owner or someone the dog is attached to leaves the dog. Dogs with separation
anxiety may exhibit one or more of the following symptoms: barking,
destructive behavior, excessive salivation, and inappropriate elimination.
Proper recognition of clinical signs, which comes from compiling a
complete patient history and assessment of the dog's household environment,
is essential to accurately diagnose and treat separation anxiety.
In clinical trials, Clomicalm Tablets, when used with behavior
modification, were shown to reduce the signs of separation anxiety and
increase the rate of improvement when compared to behavior modification alone.
Anipryl Tablets treat CDS, an age-related deterioration typified by
multiple cognitive impairments which affect the dog's ability to function
normally. Behavioral changes associated with CDS include disorientation,
decreased activity level, abnormal sleep wake cycles, loss of house training,
decreased or altered responsiveness to family members, and decreased or
altered greeting behavior.
In clinical trials, Anipryl was shown to be effective in controlling
clinical signs associated with CDS. However, onset, duration and magnitude
of response varied with individual dogs.
The diagnosis of CDS in dogs is a diagnosis of exclusion, based on
thorough behavioral and medical histories, in conjunction with appropriate
testing and diagnosis. Periodic patient monitoring to evaluate the response
and tolerance to the drug and for the presence of concurrent or emergent
disease is recommended.
Clomicalm Tablets will be sold by Novartis Animal Health US, Inc. of
Greensboro, NC. Anipryl will be sold by Pfizer, Inc. of Groton, Ct. Both
will be available in tablet form and only on the order of a veterinarian.
SOURCE Food and Drug Administration
 back to top
Related links:
http://www.fda.gov
CONTACT:
FDA: Print Media, 301-827-6242; Broadcast
Media, 301-827-3434; or Consumer Inquiries, 888-INFO-FDA
|
